Randomized, controlled, parallel-group prospective study to investigate the clinical effectiveness of early insulin treatment in patients with latent autoimmune diabetes in adults

Sinead Brophy, Helen Davies, Stephen Bain, Jeffrey W Stephens, Wei-Yee Cheung, Kez Richards, Kathie Wareham, Charles Beaverstock, Janet Lloyd, Don Page, Meurig Williams, Ian Russell, Rhys Williams, Sinead Brophy, Helen Davies, Stephen Bain, Jeffrey W Stephens, Wei-Yee Cheung, Kez Richards, Kathie Wareham, Charles Beaverstock, Janet Lloyd, Don Page, Meurig Williams, Ian Russell, Rhys Williams

Abstract

Background: Latent autoimmune diabetes in adults [LADA] is a type 1 diabetes that is slowly developing. This means many people are treated as having type 2 diabetes at diagnosis as they are adults who are not immediately insulin dependent. LADA can be distinguished from type 2 diabetes by antibody tests. Patients who are antibody positive have an autoimmune reaction which is similar to that of type 1 diabetes and is not found in type 2 diabetes. We would like to examine the best way of treating LADA in the early phase of the conditions, with tablets (similar to type 2 diabetes) or with insulin (similar to type 1 diabetes).

Methods/design: This is an open parallel group prospective randomised trial. Participants need to have a GAD antibody test results of 101 WHO units or more and a diagnosis of diabetes not requiring insulin at diagnosis. Participants will need to have been diagnosed within 12 months and not treated with insulin at study entry. They will be randomised to receive either insulin (NovoMix 30) or tablets (diet treated followed by metformin followed by glitazone (with or without metformin) followed by insulin). Primary outcome assessment will be for change in HbA1c and change in fasting C-peptide over 24 months. Secondary outcome measures will include Quality of life, GAD antibody levels, adverse events, inflammatory markers, insulin resistance, and markers of the metabolic syndrome.

Discussion: This study seeks the best treatment for early LADA in terms of maintaining glycaemic control and maintaining natural insulin production.

Trial registration: ISRCTN63815121.

Figures

Figure 1
Figure 1
Insulin treatment.
Figure 2
Figure 2
Standard treatment arm.
Figure 3
Figure 3
Schedule of visits.

References

    1. Leslie RD, Atkinson MA, Notkins AL. Autoantigens IA-2 and GAD in Type I (insulin-dependent) diabetes. Diabetologia. 1999;42:3–14. doi: 10.1007/s001250051105.
    1. Owen KR, Stride A, Ellard S, Hattersley AT. Etiological investigation of diabetes in young adults presenting with apparent type 2 diabetes. Diabetes Care. 2003;26:2088–2093. doi: 10.2337/diacare.26.7.2088.
    1. Turner R, Stratton I, Horton V, Manley S, Zimmet P, Mackay IR, Shattock M, Bottazzo GF, Holman R. UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. UK Prospective Diabetes Study Group. Lancet. 1997;350:1288–1293. doi: 10.1016/S0140-6736(97)03062-6.
    1. Maruyama T, Shimada A, Kanatsuka A, Kasuga A, Takei I, Yokoyama J, Kobayashi T. Multicenter prevention trial of slowly progressive type 1 diabetes with small dose of insulin (the Tokyo study): preliminary report. Ann N Y Acad Sci. 2003;1005:362–369. doi: 10.1196/annals.1288.060.
    1. Takino H, Yamasaki H, Sera Y, Abe T, Ozaki M, Kondo H, Sakamaki H, Kawasaki E, Yamaguchi Y, Nagataki S, Eguchi K. The preliminary report from the nation-wide prevention study for type 1 diabetes initially diagnosed as type 2 in Japan. Diabetes Metab Rev. 1998;14:334–335. doi: 10.1002/(SICI)1099-0895(199812)14:4<334::AID-DMR240>;2-H.
    1. Kobayashi T, Nakanishi K, Murase T, Kosaka K. Small doses of subcutaneous insulin as a strategy for preventing slowly progressive beta-cell failure in islet cell antibody-positive patients with clinical features of NIDDM. Diabetes. 1996;45:622–626. doi: 10.2337/diabetes.45.5.622.
    1. Zhou Z, Li X, Huang G, Peng J, Yang L, Yan X, Wang J. Rosiglitazone combined with insulin preserves islet beta cell function in adult-onset latent autoimmune diabetes (LADA) Diabetes Metab Res Rev. 2005;21:203–208. doi: 10.1002/dmrr.503.
    1. Beales PE, Pozzilli P. Thiazolidinediones for the prevention of diabetes in the non-obese diabetic (NOD) mouse: implications for human type 1 diabetes. Diabetes Metab Res Rev. 2002;18:114–117. doi: 10.1002/dmrr.262.
    1. Kobayashi T, Maruyama T, Shimada A, Kasuga A, Kanatsuka A, Takei I, Tanaka S, Yokoyama J. Insulin intervention to preserve beta cells in slowly progressive insulin-dependent (type 1) diabetes mellitus. Ann N Y Acad Sci. 2002;958:117–130.
    1. Cabrera-Rode E PP., Diaz-Horta, Tiberti C, Molina G, Arranz C, Martin J, Licea M, De Leiva A, Puig-Domingo M, Dimario U Slowly progressing type 1 diabetes: persistence of islet cell autoantibodies is related to glibenclamide treatment. Autoimmunity. 2002;35:469–474. doi: 10.1080/0891693021000050574.
    1. Brophy S BH., Davies H, Mannan S, Williams D.R.R Interventions for latent autoimmune diabetes (LADA) in adults. Cochrane Library. 2007.
    1. Bradley C, Speight J. Patient perceptions of diabetes and diabetes therapy: assessing quality of life. Diabetes Metab Res Rev. 2002;18 Suppl 3:S64–9. doi: 10.1002/dmrr.279.
    1. Levitt Katz LE, Jawad AF, Ganesh J, Abraham M, Murphy K, Lipman TH. Fasting c-peptide and insulin-like growth factor-binding protein-1 levels help to distinguish childhood type 1 and type 2 diabetes at diagnosis. Pediatr Diabetes. 2007;8:53–59. doi: 10.1111/j.1399-5448.2007.00236.x.
    1. Zhu LQ, Liu YH, Huang M, Wei H, Liu Z. [Study on improvement of islet beta cell function in patients with latent autoimmune diabetes mellitus in adults by integrative Chinese and Western medicine] Zhongguo Zhong Xi Yi Jie He Za Zhi. 2004;24:581–584.
    1. Saghaei M. Random allocation software for parallel group randomized trials. BMC Med Res Methodol. 2004;4:26. doi: 10.1186/1471-2288-4-26.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi